Quantifying Leukemia
- 27 August 1998
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 339 (9) , 627-629
- https://doi.org/10.1056/nejm199808273390911
Abstract
Measurement is the backbone of science, and the science of hematology is no exception. For many years, the number of normal or abnormal cells in the blood and bone marrow has been determined by counting cells visually or electronically and identifying them by microscopical inspection. In biologic terms, these traditional methods have very limited sensitivity, but recently developed, more sensitive techniques are providing new information of theoretical and practical value. The report by Cavé et al. in this issue of the Journal 1 indicates the value of a molecular method of quantifying leukemic cells in patients with acute lymphoblastic leukemia (ALL) . . .Keywords
This publication has 9 references indexed in Scilit:
- Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate CancerNew England Journal of Medicine, 1998
- Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 1998
- Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemiaThe Lancet, 1998
- Minimal residual disease analysis for the prediction of relapse in children with standard‐risk acute lymphoblastic leukaemiaBritish Journal of Haematology, 1998
- Monitoring minimal residual disease in peripheral blood in B‐lineage acute lymphoblastic leukaemiaBritish Journal of Haematology, 1997
- Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment responseLeukemia, 1997
- Detectable Molecular Residual Disease at the Beginning of Maintenance Therapy Indicates Poor Outcome in Children With T-Cell Acute Lymphoblastic LeukemiaBlood, 1997
- A prospective study of minimal residual disease in childhood B‐lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapseBritish Journal of Haematology, 1997
- Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of inductionThe Lancet, 1994